GlassScriptPhysician profile
Matthew Donofrio
NPI 1285607705
$8,090.52
in general payments reported to CMS, 2019-2025
38 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $681 · 2021: $747 · 2022: $1,062 · 2023: $1,292 · 2024: $1,803 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,618.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.19 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $737.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $683.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $665.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $561.77 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $538.32 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $475.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.57 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $347.95 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $247.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $228.97 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $211.39 | 2019-2022 | |
| Astellas Pharma US INC | $210.23 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $195.82 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Donofrio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.